Delivery Order SPE2DB24D2010-SPE2DB25FABCY
- Not listed
- The Defense Logistics Agency awarded a $39.7K delivery order to AmerisourceBergen Drug Corp for DUPIXENT (dupilumab) 300 mg/2 mL pen injectors on August 19, 2025, with an ultimate completion date of August 20, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of DUPIXENT 300 mg/2 mL pen injections with a ceiling value of $2,007.95. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 26, 2025. As a child contract, this delivery...
- The Defense Logistics Agency awarded a $22,738.07 firm fixed price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors (2 ML). The contract was executed on July 29, 2025, with an ultimate completion date of July 30, 2025, and is being fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside, competitively awarded contract issued under the company's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,716.90 for DUPIXENT 200 mg/1.14 ml pen auto-injectors on August 11, 2025, with completion scheduled for August 12, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $8,931.71 to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pen auto-injectors (2 mL) on September 2, 2025, with completion targeted for September 3, 2025. This non-competitive, firm fixed-price delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $3,418.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of DUPIXENT 200 mg/1.14 ml pen injectors, with an ultimate completion date of August 12, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA Troop Support Medical. The product will be performed at the contractor's location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,747.93 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform at its corporate office location. This delivery order falls under the company's broader...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $25,796.42 on August 21, 2025, by the Defense Logistics Agency's Medical Supply Chain to supply DUPIXENT 300 mg/2 mL pens. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and was competitively awarded without a set-aside designation. This award represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,709.46 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of DUPIXENT 300 mg/2 mL pens (2 mL quantity). The contract employs firm fixed price pricing with no set-aside designation, indicating competitive award status. Performance is scheduled for completion by September 4, 2025, with the place of performance located in Conshohocken, Pennsylvania, the vendor's corporate headquarters. This delivery order is issued under...
- AmerisourceBergen Drug Corp was awarded a $160,376.53 firm fixed price delivery order by the Defense Logistics Agency's Medical Supply Chain on September 9, 2025, for the supply of DUPIXENT (dupilumab) 300 mg/2 mL pen injections. The contract is non-set-aside and competitively awarded, with performance to be completed by September 10, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FABCYDelivery Order
The Defense Logistics Agency awarded a $16,294.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen injections (2 ml units) on September 9, 2025, with an ultimate completion date of September 10, 2025. This non-competitive, competitively-awarded contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime contract vehicle running through December 2026 that provides comprehensive pharmaceutical and medical supply support globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, supplies a broad portfolio of brand-name and generic medications, vaccines, and specialized medical devices to support federal military and veteran healthcare systems. DUPIXENT is a biologic immunosuppressant used to treat moderate-to-severe eczema, asthma, and other inflammatory conditions, and its procurement through DLA's medical supply chain ensures availability of this specialized pharmaceutical to Defense Health Agency and other federal healthcare beneficiaries worldwide. The contract award demonstrates AmerisourceBergen's established capability to fulfill federal medical procurement requirements through open competition and reflects its central role as a key pharmaceutical prime vendor within the military healthcare supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.3k | 9/9/25 |